Concepedia

Toyin Adewole

TA

Statistics

Publications

9

Citations

350

H-Index

9

Active since

2019

Affiliations

Supernus Pharmaceuticals (United States)(Current)

Neuroscience Education Institute

SUNY Upstate Medical University

Virginia Commonwealth University

CNS Healthcare

Toyin Adewole is an author at Supernus Pharmaceuticals (United States) specializing in pediatrics, psychopathology, and social sciences.

Top concepts

Publications per year

2019–2021

9

Publications

9

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2020 · 81 citations · Full text

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Janet Johnson, Tesfaye Liranso, Keith E. Saylor et al. · Journal of Attention Disorders · 2019 · 60 citations · Full text

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2021 · 53 citations

, , +11

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Journal of Clinical Psychopharmacology · 2021 · 40 citations · Full text

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · PubMed · 2021 · 36 citations · Full text

1–5 of 9